Replies to post #240758 on Biotech Values

[DewDiligence]

FDA approves PFE’s Cibinqo (abrocitinib) for second-line atopic dermatitis:

https://finance.yahoo.com/news/u-fda-approves-pfizer-cibinqo-203000030.html

Cibinqo, an oral JAK1 inhibitor, figures to be a big-selling drug that can move the needle even for a company as large as PFE. It has shown superior efficacy to market-leading Dupixent (#msg-165687423).

Cibinqo was already approved for atopic dermatitis—including the first-line setting—in the EU, Great Britain, Japan, Korea, the UAE, Norway, Iceland, and Singapore. Only the FDA is sufficiently concerned about the safety of the JAK class to restrict Cibionqo (and other JAKs such as ABBV’s Rinvoq) to the second-line setting.